Osang Healthcare
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Osang Healthcare makes in-vitro diagnostic (IVD) products, devices and test kits that analyse blood, saliva, or other bodily fluids outside the body to detect disease, guide treatment, and inform prescriptions.
Its products span three diagnostic categories: biochemical tests (including portable blood-glucose and cholesterol monitors), immunoassay-based tests (such as quantitative analysers for cardiac, cancer, and hormonal conditions, and rapid antigen kits for respiratory infections), and molecular diagnostics that detect genetic material using PCR technology. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company distributes its products internationally, including through dedicated subsidiaries in the United States and Brazil.
Summary is AI-generated and may contain errors · figures from DART filings
Osang Healthcare operates dedicated distribution subsidiaries, OSANG LLC in the United States and OSANG DO BRASIL LIMITADA in Brazil, handling overseas sales directly rather than through third-party distributors.
Osang Healthcare in five facts
What does Osang Healthcare do?
Osang Healthcare makes in-vitro diagnostic (IVD) products, devices and test kits that analyse blood, saliva, or other bodily fluids outside the body to detect disease, guide treatment, and inform prescriptions.
Where is Osang Healthcare listed and in which sector?
Osang Healthcare (Korean name: 오상헬스케어) trades under KRX code 036220 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Osang Healthcare?
Its market capitalisation was US$64.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Osang Healthcare's latest annual revenue and operating profit?
For fiscal year 2025, Osang Healthcare reported revenue of US$97.1M, operating profit of US$1.8M and net income of US$2.3M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 59.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Supply contract signed (voluntary)
Osang Healthcare disclosed a supply contract with HemoCue AB, worth US$4.4M, about 5.1% of its recent annual revenue, running through Nov 2026.
Supply contract · May 13 - Treasury share disposal: results reportTreasury Shares · May 12
- Material event report (treasury share disposal)
Osang Healthcare disclosed a plan to sell treasury shares worth US$52.8K, about 0.1% of its market value.
Treasury Shares · Mar 20 - Cash/in-kind dividend decision
Osang Healthcare declared a cash dividend of US$0.14 per share, equal to about 2% of the recent share price.
Dividend · Mar 10 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Osang Healthcare reported consolidated results for FY2025: revenue of US$87.8M (+59.8% year on year), operating profit of US$1.66M (from a loss a year earlier) and net income of US$2.12M (from a loss a year earlier).
Earnings · Mar 10